One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis
© 2019 Massachusetts Medical Society. BACKGROUND Tuberculosis is the leading killer of patients with human immunodeficiency virus (HIV) infection. Preventive therapy is effective, but current regimens are limited by poor implementation and low completion rates. METHODS We conducted a randomized, ope...
Saved in:
相似書籍
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
由: Anthony T. Podany, et al.
出版: (2018) -
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
由: Anthony T. Podany, et al.
出版: (2018) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
由: Jyoti S. Mathad, et al.
出版: (2022) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
由: Mathad J.S.
出版: (2023) -
Change in vitamin D levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings
由: Fiona P. Havers, et al.
出版: (2018)